Thomas Fontaine
Associate Scientist Confo Therapeutics
Seminars
Thursday 30th April 2026
Advancing Antibody Discovery for GPCR Targets Through In Vivo Validation of an Agonistic Antibody
11:30 am
- Describing the discovery strategy used to generate an agonistic antibody, including target selection and screening approaches
- Demonstrating in vivo validation of the agonistic antibody and the pharmacological activity observed across relevant models
- Detailing key translational learnings from the program and how these insights inform broader GPCR-directed antibody discovery efforts
